Literature DB >> 16460539

Prevalence surveys of healthcare-associated infections: what do they tell us, if anything?

H Humphreys, E T M Smyth.   

Abstract

Prevalence surveys of healthcare-associated infections offer advantages over incidence surveys, including the relative ease of performance, a reduced requirement for resources, the ability to include increased numbers of hospitals within a shorter period of time, and the possibility of more rapid data analysis and feedback. Prevalence surveys have also been shown to be useful in monitoring the effectiveness of infection control programmes. Prevalence surveys appear to be desirable when financial support, and/or the will to carry out incidence surveys, is lacking. However, it is imperative that prevalence surveys use standardised methodology and internationally recognised definitions of infection.

Entities:  

Mesh:

Year:  2006        PMID: 16460539     DOI: 10.1111/j.1469-0691.2005.01273.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  11 in total

1.  Trial of a novel plasma gas disinfection system (Radica) to reduce mattress residual bacterial contamination in the acute hospital setting: a preliminary study.

Authors:  F Shiely; D Fallon; C Casey; D M Kerins; J A Eustace
Journal:  Ir J Med Sci       Date:  2016-01-21       Impact factor: 1.568

2.  A national point prevalence study on healthcare-associated infections and antimicrobial use in Austria.

Authors:  Luigi Segagni Lusignani; Alexander Blacky; Peter Starzengruber; Magda Diab-Elschahawi; Thomas Wrba; Elisabeth Presterl
Journal:  Wien Klin Wochenschr       Date:  2016-01-27       Impact factor: 1.704

3.  Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010.

Authors:  Mete Cek; Zafer Tandoğdu; Florian Wagenlehner; Peter Tenke; Kurt Naber; Truls Erik Bjerklund-Johansen
Journal:  World J Urol       Date:  2014-01-23       Impact factor: 4.226

4.  Using surveillance data to reduce healthcare-associated infection: a qualitative study in Sweden.

Authors:  Mikaela Ridelberg; Per Nilsen
Journal:  J Infect Prev       Date:  2015-06-04

5.  Factors associated with seroprevalence of hepatitis C among dentists at a large Brazilian city.

Authors:  Vera Lúcia S Resende; Mauro Henrique G Abreu; Saul M Paiva; Rosângela Teixeira; Isabela A Pordeus
Journal:  Virol J       Date:  2009-12-23       Impact factor: 4.099

6.  Sensitivity and specificity of the method used for ascertainment of healthcare-associated infections in the second Slovenian national prevalence survey.

Authors:  Mojca Serdt; Tatjana Lejko Zupanc; Aleš Korošec; Irena Klavs
Journal:  Zdr Varst       Date:  2016-07-28

7.  Reducing the risk of healthcare-associated infections through Lean Six Sigma: The case of the medicine areas at the Federico II University Hospital in Naples (Italy).

Authors:  Giovanni Improta; Mario Cesarelli; Paolo Montuori; Liberatina Carmela Santillo; Maria Triassi
Journal:  J Eval Clin Pract       Date:  2017-11-03       Impact factor: 2.431

8.  Skin and soft tissue infections and current antimicrobial prescribing practices in Australian aged care residents.

Authors:  N J Bennett; N Imam; R J Ingram; R S James; K L Buising; A L Bull; C S Chen; K A Thursky; L J Worth
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

9.  Annual surveys for point-prevalence of healthcare-associated infection in a tertiary hospital in Beijing, China, 2012-2014.

Authors:  Yaowen Zhang; Jing Zhang; Dong Wei; Zhirong Yang; Yanyan Wang; Zhiyuan Yao
Journal:  BMC Infect Dis       Date:  2016-04-18       Impact factor: 3.090

10.  Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017.

Authors:  Eline Vandael; Katrien Latour; Herman Goossens; Koen Magerman; Nico Drapier; Boudewijn Catry; Ann Versporten
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-13       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.